RxDoctor Payments Data

Christoph Salerno, DO

Family Medicine · Willingboro, NJNPI 1194838060

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 43 payments — averaging $28.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$442
  • Novo Nordisk$369
  • AbbVie$344
  • Sunovion Pharmaceuticals Inc.$27
  • Astellas Pharma US Inc$17
  • GSK$14
  • plus $26 from 2 others

What the payments were for

  • Travel & lodging$13411%
  • Food & beverage$1,10489%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$86,228
Medicare patients
248
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$234,349
JardianceEmpagliflozin78$88,418
EliquisApixaban93$78,172
FarxigaDapagliflozin Propanediol31$37,677
XareltoRivaroxaban36$33,597
MounjaroTirzepatide20$30,192
Diclofenac Potassium15$26,867
Humulin R U-500 KwikpenInsulin Regular, Human16$25,035
OxycontinOxycodone Hcl24$17,949
InvokanaCanagliflozin11$10,726
Breo ElliptaFluticasone/Vilanterol26$9,857
MovantikNaloxegol Oxalate13$8,704
MyrbetriqMirabegron15$7,660
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$7,471
Dexlansoprazole DrDexlansoprazole12$6,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$369$234,349169 claims
Johnson & JohnsonXarelto, Invokana$13$44,32347 claims
GSKBreo Ellipta$14$9,85726 claims
Astellas Pharma US IncMyrbetriq$17$7,66015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Willingboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →